A Phase 4 interventional study of Secukinumab in Plaque Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 215 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-25.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Pruritus by Novartis — 2 open to participants now, 2 under way, 2 of them phase 3. Pruritus · Novartis.
Among the 17 studies in Pruritus by Novartis, this one has the largest enrollment, is the only one that started in 2016, is one of 2 in phase 4, and was the 7th registered.
491 studies on the registry are indexed under Pruritus; 94 are open to participants now.
Browse Pruritus studies →2 of the 17 studies in Pruritus by Novartis are open now, in 6 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Canada, China
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Argentina, Canada and 2 more countries
Ages 18+
By country, each count listing its studies:
Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,660 is above the median of 60 across 423 interventional studies indexed under Pruritus.
Median enrollment 182 across the 17 interventional studies. Of the 15 that completed or were terminated, 14 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Pruritus by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis in patients with or without prior exposure to systemic therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients are received s.c. injections of secukinumab 300 mg at Week 0, 1, 2 and 3 during the first 4 weeks followed by monthly maintenance dosing of 300 mg secukinumab starting at Week 4 until Week 48. Consideration was given to discontinuing treatment in patients who showed no response up to 16 weeks of treatment (e.g. patients who did not achieve a PASI 50 response). If discontinued, patients completed the end of study visit assessments. Some patients with an initially partial response (e.g. patients who achieved a PASI 50 response but not a PASI 75 response) subsequently improved with continued treatment beyond 16 weeks.
Drug: Secukinumab
Secukinumab was used as commercially available PFS of 150 mg. Patients received PFS at the site and were instructed to administer Secukinumab as needed (300 mg each application).
Also known as: AIN457
Percentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Week 16
The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.
Time frame: 16 weeks
Percentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Week 52
The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.
Time frame: 52 weeks
Percentage of Participants in Each DLQI Score Category at Week 16 and Week 52
The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.
Time frame: 52 weeks
Percentage of Participants With PASI 50, PASI 75, PASI 90, PASI 100 or IGA Mod 2011 0/1 Response at Week 16 and 52
PASI is a combined assessment of lesion severity \& affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself \& scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), \& severity is estimated by clinical signs, erythema, induration \& desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 \& 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.
Time frame: Week 16, Week 52
Absolute Change From Baseline in EQ-5D-5L Crosswalk Index at Week 16 and Week 52
The EQ-5D descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort \& anxiety/depression. The 5 dimensions have 5 response levels scored from 1 (best) to 5 (worst). The first 3 dimensions have the response levels lasting from no problems, slight problems, moderate problems, severe problems to unable; the last 2 dimensions have the 5 response levels lasting from no, slight, moderate, severe to extreme. From these 5 dimensions the Crosswalk-index is calculated by concatenating the responses \& choosing the corresponding country specific index value from the EQ-5D-5L_Crosswalk_Index_Value_Calculator.v2 excel file (https://euroqol.org/eq-5d-instruments/eq-5d-5labout/valuation-standard-value-sets/crosswalk-index-value-calculator/). This calculated participant-level index scores from -0.654 (worst health) to 1.0 (best health).
Time frame: Week 16, Week 52
Absolute Change From Baseline in EQ-5D-5L Visual Analogue Scale (VAS) at Week 16 and Week 52
A visual analogue scale (VAS) was used within the EQ-5D. This scale recorded the respondent's self-rated health on a vertical 20-cm VAS where the endpoints were labeled "best imaginable health state" and "worst imaginable health state." This resulted in a numeric value set ranging from 0 (="worst imaginable health state") up to 100 (="best imaginable health state").
Time frame: Week 16, Week 52
Absolute Change From Baseline in HAQ-DI at Week 16 and Week 52
The HAQ-DI (Health Assessment Questionnaire - Disability Index) assesses a patient's level of functional ability \& includes questions on fine movements of the upper extremity, locomotor activities of the lower extremity \& activities that involve both upper \& lower extremities. There are 20 items in 8 categories of functioning including dressing \& grooming, arising, eating, walking, hygiene, reach, grip \& usual activities. The stem of each item asks over the past week, "Are you able to..." perform a particular task. Each item is scored on a 4-point scale from 0 to 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) \& unable to do (3). The HAQ-DI also includes questions about the use of 'aids or devices' \& aid from other people to supplement the answers given to the 20 items. Total scores were calculated by averaging all scores and ranging from 0 (best) to 3 (worst). Subtracting the baseline value from the week 16 or 52 values results in the change.
Time frame: Week 16 and Week 52
Absolute Change From Baseline in Numeric Rating Scale (NRS) at Week 16 and Week 52
Selfadministered 11-point numeric rating scales (NRS, 0-10) were used to evaluate the patients' assessment of their current pain, itching \& scaling. Respondents answered the following questions for the assessment: Pain: Overall, how severe was your psoriasis-related pain over the past 24 hours?; Itching: Overall, how severe was your psoriasis-related itch over the past 24 hours?; \& Scaling: Overall, how severe was your psoriasis related scaling over the past 24 hours? Patients had to rate their pain, itching, \& scaling from 0 to 10 (11-point scale), with the understanding that the 0 represents the absence or null end of the pain, itching, or scale intensity (i.e. no pain, itching or scaling) \& the 10 represents the other extreme of pain, itching, or scaling intensity (i.e. pain, itching or scaling as bad as it could be). The number that the patient selected represents his or her intensity score in the respective category.
Time frame: 16 and 52 weeks
Treatment Satisfaction Questionnaire for Medication (TSQM) Scale Scores at Week 16 and Week 52
Treatment Satisfaction Questionnaire for Medication (TSQM) is general measure for treatment satisfaction. Each scale score was calculated by summing individual items and then transformed to a 0-100 scale. Higher summary scores indicate better satisfaction with study drug.
Time frame: 16 and 52 weeks
Patient Benefit Index (PBI) at Week 16 and Week 52
The questionnaire includes 23 items on patient-relevant therapy needs \& benefits. The first part of the instrument, the 'Patient Needs Questionnaire' (PNQ), is filled in by the patient before therapy. A 5-step Likert scale (0='not important at all' to 4='very important') records the individual relevance of the different items to the patients. The second part, the PBQ, is filled in by the patient during or after therapy. It comprises the same items as the PNQ, but in contrast, the patients evaluate the extent to which the treatment needs have been fulfilled by therapy (scaled from 0='treatment did not help at all' to 4='treatment helped a lot'). In addition, the Likert scale contains the option 'does not apply to me' in the PNQ \& the option 'did not apply to me' in the PBQ. The needs prior to treatment (PNQ) \& the benefits achieved by treatment (PBQ) are converted to a weighted index value, the PBI in the narrower sense. PBI can have a value from 0='no benefit' to 4='maximal benefit'.
Time frame: Week 16 and Week 52
A total of 1660 participants were treated and included in the Safety set.
| Milestone | Subpopulation A (Naive) | Subpopulation B (Non-biologic) | Subpopulation C (Biologic) |
|---|---|---|---|
| Started | 663 | 673 | 324 |
| Completed | 611 | 597 | 276 |
| Not completed | 52 | 76 | 48 |
| Withdrew: Adverse event | 15 | 23 | 11 |
| Withdrew: Lack of efficacy | 2 | 6 | 14 |
| Withdrew: Lost to follow-up | 11 | 12 | 4 |
| Withdrew: Non-compliance with study treatment | 0 | 0 | 1 |
| Withdrew: Physician decision | 2 | 6 | 2 |
| Withdrew: Pregnancy | 1 | 6 | 3 |
| Withdrew: Protocol violation | 10 | 13 | 6 |
| Withdrew: Subject/guardian decision | 8 | 6 | 4 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 4 | 2 |
The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.
| Percentage of participants | Subpopulation A (Naive) | Subpopulation B (Non-biologic) | Subpopulation C (Biologic) | All Participants |
|---|---|---|---|---|
| Percentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Week 16 | 74.7 (71.2 to 78.0) | 71.3 (67.7 to 74.7) | 61.7 (56.1 to 67.0) | 70.8 (68.5 to 73.0) |
The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.
| Percentage of participants | Subpopulation A (Naive) | Subpopulation B (Non-biologic) | Subpopulation C (Biologic) | All Participants |
|---|---|---|---|---|
| Percentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Week 52 | 75.3 (71.7 to 78.5) | 73.3 (69.8 to 76.6) | 62.0 (56.5 to 67.3) | 71.9 (69.6 to 74.0) |
The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.
| Percentage of participants | Subpopulation A (Naive) | Subpopulation B (Non-biologic) | Subpopulation C (Biologic) | All Participants |
|---|---|---|---|---|
| Wk 16: DLQI cat. score: 2-5 | 18.3 (15.5 to 21.6) | 19.1 (16.2 to 22.3) | 21.2 (16.9 to 26.2) | 19.2 (17.3 to 21.2) |
| Wk 16: DLQI cat. score: 6-10 | 5.7 (4.1 to 7.8) | 6.3 (4.6 to 8.5) | 9.3 (6.5 to 13.2) | 6.7 (5.5 to 8.0) |
| Wk 16: DLQI cat. score: 11-20 | 1.2 (0.6 to 2.5) | 2.9 (1.8 to 4.5) | 5.3 (3.2 to 8.5) | 2.7 (2.0 to 3.6) |
| Wk 16:DLQI cat. score: 21-30 | 0.0 (0.0 to 0.7) | 0.5 (0.1 to 1.4) | 2.5 (1.2 to 5.0) | 0.7 (0.4 to 1.2) |
| Wk 52: DLQI cat. score: 2-5 | 17.9 (15.0 to 21.1) | 14.0 (11.5 to 16.9) | 18.2 (14.2 to 23.0) | 16.4 (14.6 to 18.3) |
| Wk 52: DLQI cat. score: 6-10 | 4.7 (3.3 to 6.7) | 7.2 (5.4 to 9.4) | 9.6 (6.7 to 13.4) | 6.7 (5.5 to 8.0) |
| Wk 52:DLQI cat. score: 11-20 | 1.8 (1.0 to 3.3) | 4.0 (2.7 to 5.9) | 8.3 (5.7 to 12.0) | 4.0 (3.1 to 5.1) |
| Wk 52:DLQI cat. score: 21-30 | 0.3 (0.1 to 1.2) | 1.5 (0.8 to 2.8) | 1.9 (0.8 to 4.2) | 1.1 (0.7 to 1.8) |
PASI is a combined assessment of lesion severity \& affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself \& scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), \& severity is estimated by clinical signs, erythema, induration \& desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 \& 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.
| Percentage of participants | Subpopulation A (Naive) | Subpopulation B (Non-biologic) | Subpopulation C (Biologic) | All Participants |
|---|---|---|---|---|
| Wk 16: PASI 50 | 97.7 (96.2 to 98.7) | 97.5 (95.9 to 98.5) | 95.0 (91.9 to 97.2) | 97.1 (96.1 to 97.8) |
| Wk 16: PASI 75 | 94.4 (92.3 to 96.0) | 92.8 (90.5 to 94.7) | 85.4 (81.0 to 89.1) | 92.0 (90.6 to 93.3) |
| Wk 16: PASI 90 | 82.4 (79.2 to 85.2) | 78.8 (75.5 to 81.8) | 69.0 (63.6 to 74.0) | 78.3 (76.2 to 80.3) |
| Wk 16: PASI 100 | 47.3 (43.4 to 51.2) | 38.8 (35.1 to 42.6) | 33.4 (28.4 to 38.9) | 41.1 (38.7 to 43.6) |
| Wk 16: IGA 0/1 | 87.4 (84.5 to 89.8) | 84.9 (82.0 to 87.5) | 76.2 (71.1 to 80.7) | 84.2 (82.3 to 85.9) |
| Wk 52: PASI 50 | 97.9 (96.4 to 98.9) | 96.3 (94.5 to 97.6) | 92.9 (89.4 to 95.5) | 96.3 (95.2 to 97.1) |
| Wk 52: PASI 75 | 94.4 (92.3 to 96.0) | 89.7 (87.1 to 91.9) | 83.3 (78.7 to 87.2) | 90.4 (88.8 to 91.7) |
| Wk 52: PASI 90 | 80.8 (77.6 to 83.7) | 75.5 (72.0 to 78.7) | 63.9 (58.4 to 69.1) | 75.3 (73.2 to 77.4) |
| Wk 52: PASI 100 | 56.9 (53.1 to 60.8) | 45.5 (41.7 to 49.3) | 37.0 (31.8 to 42.6) | 48.4 (46.0 to 50.8) |
| Wk 52: IGA 0/1 | 86.4 (83.5 to 88.9) | 79.9 (76.7 to 82.9) | 71.3 (66.0 to 76.1) | 80.8 (78.8 to 82.7) |
The EQ-5D descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort \& anxiety/depression. The 5 dimensions have 5 response levels scored from 1 (best) to 5 (worst). The first 3 dimensions have the response levels lasting from no problems, slight problems, moderate problems, severe problems to unable; the last 2 dimensions have the 5 response levels lasting from no, slight, moderate, severe to extreme. From these 5 dimensions the Crosswalk-index is calculated by concatenating the responses \& choosing the corresponding country specific index value from the EQ-5D-5L_Crosswalk_Index_Value_Calculator.v2 excel file (https://euroqol.org/eq-5d-instruments/eq-5d-5labout/valuation-standard-value-sets/crosswalk-index-value-calculator/). This calculated participant-level index scores from -0.654 (worst health) to 1.0 (best health).
| scores on a scale | Subpopulation A (Naive) | Subpopulation B (Non-biologic) | Subpopulation C (Biologic) | All Participants |
|---|---|---|---|---|
| Week 16 | 0.217 ± 0.2294 | 0.201 ± 0.2277 | 0.235 ± 0.2602 | 0.214 ± 0.2352 |
| Week 52 | 0.221 ± 0.2353 | 0.193 ± 0.2360 | 0.226 ± 0.2596 | 0.211 ± 0.2408 |
A visual analogue scale (VAS) was used within the EQ-5D. This scale recorded the respondent's self-rated health on a vertical 20-cm VAS where the endpoints were labeled "best imaginable health state" and "worst imaginable health state." This resulted in a numeric value set ranging from 0 (="worst imaginable health state") up to 100 (="best imaginable health state").
| scores on a scale | Subpopulation A (Naive) | Subpopulation B (Non-biologic) | Subpopulation C (Biologic) | All Participants |
|---|---|---|---|---|
| Week 16 | 19.7 ± 24.36 | 21.4 ± 25.66 | 18.7 ± 26.66 | 20.2 ± 25.36 |
| Week 52 | 21.7 ± 24.11 | 22.6 ± 25.47 | 19.5 ± 25.14 | 21.7 ± 24.88 |
The HAQ-DI (Health Assessment Questionnaire - Disability Index) assesses a patient's level of functional ability \& includes questions on fine movements of the upper extremity, locomotor activities of the lower extremity \& activities that involve both upper \& lower extremities. There are 20 items in 8 categories of functioning including dressing \& grooming, arising, eating, walking, hygiene, reach, grip \& usual activities. The stem of each item asks over the past week, "Are you able to..." perform a particular task. Each item is scored on a 4-point scale from 0 to 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) \& unable to do (3). The HAQ-DI also includes questions about the use of 'aids or devices' \& aid from other people to supplement the answers given to the 20 items. Total scores were calculated by averaging all scores and ranging from 0 (best) to 3 (worst). Subtracting the baseline value from the week 16 or 52 values results in the change.
| scores on a scale | Subpopulation A (Naive) | Subpopulation B (Non-biologic) | Subpopulation C (Biologic) | All Participants |
|---|---|---|---|---|
| Week 16 | -0.7 ± 0.97 | -0.5 ± 0.83 | -0.3 ± 0.85 | -0.5 ± 0.87 |
| Week 52 | -0.7 ± 0.90 | -0.5 ± 0.90 | -0.4 ± 0.85 | -0.5 ± 0.88 |
Selfadministered 11-point numeric rating scales (NRS, 0-10) were used to evaluate the patients' assessment of their current pain, itching \& scaling. Respondents answered the following questions for the assessment: Pain: Overall, how severe was your psoriasis-related pain over the past 24 hours?; Itching: Overall, how severe was your psoriasis-related itch over the past 24 hours?; \& Scaling: Overall, how severe was your psoriasis related scaling over the past 24 hours? Patients had to rate their pain, itching, \& scaling from 0 to 10 (11-point scale), with the understanding that the 0 represents the absence or null end of the pain, itching, or scale intensity (i.e. no pain, itching or scaling) \& the 10 represents the other extreme of pain, itching, or scaling intensity (i.e. pain, itching or scaling as bad as it could be). The number that the patient selected represents his or her intensity score in the respective category.
| scores on a scale | Subpopulation A (Naive) | Subpopulation B (Non-biologic) | Subpopulation C (Biologic) | All Participants |
|---|---|---|---|---|
| Pain: Wk 16 | -3.0 ± 2.87 | -3.3 ± 3.11 | -3.3 ± 3.30 | -3.2 ± 3.06 |
| Pain: Wk 52 | -3.1 ± 2.95 | -3.2 ± 3.22 | -3.3 ± 3.36 | -3.2 ± 3.14 |
| Itching: Wk 16 | -4.9 ± 2.96 | -4.9 ± 3.06 | -4.8 ± 3.31 | -4.9 ± 3.07 |
| Itching: Wk 52 | -5.0 ± 2.92 | -5.0 ± 3.10 | -4.6 ± 3.28 | -4.9 ± 3.07 |
| Scaling: Wk 16 | -5.5 ± 2.68 | -5.5 ± 2.71 | -5.2 ± 3.26 | -5.4 ± 2.81 |
| Scaling: Wk 52 | -5.4 ± 2.72 | -5.3 ± 2.87 | -4.9 ± 3.27 | -5.3 ± 2.90 |
Treatment Satisfaction Questionnaire for Medication (TSQM) is general measure for treatment satisfaction. Each scale score was calculated by summing individual items and then transformed to a 0-100 scale. Higher summary scores indicate better satisfaction with study drug.
| scores on a scale | Subpopulation A (Naive) | Subpopulation B (Non-biologic) | Subpopulation C (Biologic) | All Participants |
|---|---|---|---|---|
| Effectiveness: Wk 16 | 81.5 ± 24.02 | 80.9 ± 25.13 | 75.0 ± 23.43 | 80.0 ± 24.48 |
| Effectiveness: Wk 52 | 85.1 ± 20.64 | 82.0 ± 25.05 | 74.9 ± 24.24 | 81.9 ± 23.50 |
| Convenience: Wk 16 | 79.2 ± 15.50 | 80.8 ± 15.83 | 75.9 ± 15.20 | 79.2 ± 15.67 |
| Convenience: Wk 52 | 82.8 ± 15.67 | 83.9 ± 15.42 | 78.9 ± 15.14 | 82.5 ± 15.57 |
| Global satisfaction: Wk 16 | 83.8 ± 14.71 | 83.3 ± 16.68 | 75.1 ± 20.07 | 81.9 ± 16.99 |
| Global satisfaction: Wk 52 | 83.9 ± 17.23 | 81.9 ± 20.38 | 73.5 ± 23.10 | 81.1 ± 20.14 |
The questionnaire includes 23 items on patient-relevant therapy needs \& benefits. The first part of the instrument, the 'Patient Needs Questionnaire' (PNQ), is filled in by the patient before therapy. A 5-step Likert scale (0='not important at all' to 4='very important') records the individual relevance of the different items to the patients. The second part, the PBQ, is filled in by the patient during or after therapy. It comprises the same items as the PNQ, but in contrast, the patients evaluate the extent to which the treatment needs have been fulfilled by therapy (scaled from 0='treatment did not help at all' to 4='treatment helped a lot'). In addition, the Likert scale contains the option 'does not apply to me' in the PNQ \& the option 'did not apply to me' in the PBQ. The needs prior to treatment (PNQ) \& the benefits achieved by treatment (PBQ) are converted to a weighted index value, the PBI in the narrower sense. PBI can have a value from 0='no benefit' to 4='maximal benefit'.
| scores on a scale | Subpopulation A (Naive) | Subpopulation B (Non-biologic) | Subpopulation C (Biologic) | All Participants |
|---|---|---|---|---|
| Week 16 | 3.5 ± 0.61 | 3.4 ± 0.69 | 3.2 ± 0.85 | 3.4 ± 0.70 |
| Week 52 | 3.5 ± 0.70 | 3.4 ± 0.80 | 3.2 ± 0.96 | 3.4 ± 0.80 |
Collected over All Adverse Events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit for up to 52 weeks.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Subpopulation A (Naive) | 0/663 (0%) | 43/663 (6.5%) | 450/663 (67.9%) |
| Subpopulation B (Non-biologic) | 0/673 (0%) | 44/673 (6.5%) | 474/673 (70.4%) |
| Subpopulation C (Biologic) | 1/324 (0.3%) | 32/324 (9.9%) | 203/324 (62.7%) |
| All Participants | 1/1,660 (0.1%) | 119/1,660 (7.2%) | 1,127/1,660 (67.9%) |
| Event | Subpopulation A (Naive) | Subpopulation B (Non-biologic) | Subpopulation C (Biologic) | All Participants |
|---|---|---|---|---|
| Ischaemic strokeNervous system disorders | 0/663 | 0/673 | 3/324 | 3/1660 |
| Pelvic fractureInjury, poisoning and procedural complications | 0/663 | 0/673 | 2/324 | 2/1660 |
| NephrolithiasisRenal and urinary disorders | 0/663 | 1/673 | 2/324 | 3/1660 |
| PsoriasisSkin and subcutaneous tissue disorders | 1/663 | 2/673 | 2/324 | 5/1660 |
| ErysipelasInfections and infestations | 4/663 | 2/673 | 0/324 | 6/1660 |
| Crohn's diseaseGastrointestinal disorders | 1/663 | 3/673 | 0/324 | 4/1660 |
| Angina pectorisCardiac disorders | 1/663 | 0/673 | 1/324 | 2/1660 |
| Cardiac failureCardiac disorders | 0/663 | 0/673 | 1/324 | 1/1660 |
| VertigoEar and labyrinth disorders | 0/663 | 0/673 | 1/324 | 1/1660 |
| Pupils unequalEye disorders | 0/663 | 0/673 | 1/324 | 1/1660 |
| Event | Subpopulation A (Naive) | Subpopulation B (Non-biologic) | Subpopulation C (Biologic) | All Participants |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 189/663 | 189/673 | 66/324 | 444/1660 |
| HeadacheNervous system disorders | 76/663 | 79/673 | 21/324 | 176/1660 |
| Back painMusculoskeletal and connective tissue disorders | 31/663 | 46/673 | 15/324 | 92/1660 |
| PsoriasisSkin and subcutaneous tissue disorders | 20/663 | 36/673 | 22/324 | 78/1660 |
| Upper respiratory tract infectionInfections and infestations | 39/663 | 25/673 | 20/324 | 84/1660 |
| PruritusSkin and subcutaneous tissue disorders | 31/663 | 41/673 | 13/324 | 85/1660 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 34/663 | 40/673 | 14/324 | 88/1660 |
| RhinitisInfections and infestations | 37/663 | 37/673 | 11/324 | 85/1660 |
| CoughRespiratory, thoracic and mediastinal disorders | 37/663 | 31/673 | 12/324 | 80/1660 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 26/663 | 28/673 | 18/324 | 72/1660 |
Safety set: The Safety set included all patients who received at least 1 dose of study drug.
| Age, Continuous(years) | Subpopulation A (Naive) | Subpopulation B (Non-biologic) | Subpopulation C (Biologic) | Total |
|---|---|---|---|---|
| Mean | 43.2 ± 14.03 | 44.4 ± 13.67 | 47.4 ± 12.89 | 44.5 ± 13.74 |
| Sex: Female, Male(Participants) | Subpopulation A (Naive) | Subpopulation B (Non-biologic) | Subpopulation C (Biologic) | Total |
|---|---|---|---|---|
| Female | 224 | 222 | 107 | 553 |
| Male | 439 | 451 | 217 | 1107 |
| Race/Ethnicity, Customized(Participants) | Subpopulation A (Naive) | Subpopulation B (Non-biologic) | Subpopulation C (Biologic) | Total |
|---|---|---|---|---|
| Caucasian | 626 | 642 | 307 | 1575 |
| Black | 3 | 2 | 0 | 5 |
| Asian | 12 | 6 | 2 | 20 |
| Other | 22 | 23 | 15 | 60 |
Showing the first 100 of 215 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Supporting information: Study protocol, Statistical analysis plan
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Mar 2016 to primary completion in Mar 2018, 24 months.
Results were first posted in Sep 2019, 1 year 5 months after primary completion.
Of 19 phase 4 interventional studies under Pruritus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 33. This study's 24 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab